Fake Drug Peddler Banned from U.S. Imports for Decade.
Published Date: 3/13/2025
Notice
Summary
Jonathan Corbett Cosie is banned for 10 years from importing any drugs into the U.S. because he was convicted of selling fake or mislabeled drugs to trick people. He didn’t respond to the FDA’s notice, so the ban started on March 13, 2025. He can apply to end the ban anytime, but must follow special rules to keep personal info private.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
10-year ban on importing drugs
Jonathan Corbett Cosie is debarred for 10 years from importing or offering for import any drug into the United States, effective March 13, 2025. The debarment follows his July 30, 2024 conviction for two felony counts for introducing misbranded drugs into interstate commerce.
Prohibition on importing with his assistance
Under section 301(cc) of the FD&C Act, importing or offering for import any drug into the United States by, with the assistance of, or at the direction of Mr. Cosie is a prohibited act effective March 13, 2025. Businesses or persons that would rely on Mr. Cosie to import drugs cannot lawfully do so while the debarment is in effect.
How to apply to end debarment and privacy rules
Mr. Cosie may apply at any time to terminate his debarment under section 306(d)(1). Electronic applications submitted to https://www.regulations.gov (including attachments) will be posted to the public docket unchanged; to submit confidential information, he must file a written/paper application with two copies (one marked confidential and one redacted) following the FDA instructions.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-04029, Alnashir Alibhai Punjani: Final Debarment Order
Alnashir Alibhai Punjani is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving unapproved drugs. He didn’t respond to the FDA’s notice, so the ban starts on March 13, 2025. Punjani can apply to end the ban anytime, but must follow strict rules to keep personal info private.
Next: 2025-04031, John Warrington Kosolcharoen: Final Debarment Order
John Warrington Kosolcharoen is permanently banned by the FDA from working with any drug companies because he was convicted of a serious crime related to drug regulations. He didn’t respond to the FDA’s notice, so the ban starts on March 13, 2025, and lasts forever unless he applies to end it. This means he can’t be involved in drug approvals or related work, impacting his career and any companies he might have worked with.